








Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice.
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Hydrogen sulfide (H2S) has been highlighted as an endogenous signaling molecule and we have previously found that it can inhibit histamine-mediated itching. Pruritus is the most common symptom of cutaneous diseases and anti-histamines are the usual treatment; however, anti-histamine-resistant pruritus is common in some clinical settings. In this way, the involvement of mediators other than histamine in the context of pruritus requires new therapeutic targets. Considering that the activation of proteinase-activated receptor 2 (PAR-2) is involved in pruritus both in rodents and humans, in this study we investigated the effect of H2S donors on the acute scratching behavior mediated by PAR-2 activation in mice, as well as some of the possible pharmacological mechanisms involved. The intradermal injection of the PAR-2 peptide agonist SLIGRL-NH2 (8-80 nmol) caused a dose-dependent scratching that was unaffected by intraperitoneal pre-treatment with the histamine H1 antagonist pyrilamine (30 mg/kg). Co-injection of SLIGRL-NH2 (40 nmol) with either the slow-release H2S donor GYY4137 (1 and 3 nmol) or the spontaneous donor NaHS (1 and 0.3 nmol) significantly reduced pruritus. Co-treatment with the KATP channel blocker glibenclamide (200 nmol) or the nitric oxide (NO) donor sodium nitroprusside (10 nmol) abolished the antipruritic effects of NaHS; however, the specific soluble guanylyl cyclase inhibitor ODQ (30 μg) had no significant effects. The transient receptor potential ankyrin type 1 (TRPA1) antagonist HC-030031 (20 μg) significantly reduced SLIGRL-NH2-induced pruritus; however pruritus induced by the TRPA1 agonist AITC (1000 nmol) was unaffected by NaHS. Based on these data, we conclude that pruritus secondary to PAR-2 activation can be reduced by H2S, which acts through KATP channel opening and involves NO in a cyclic guanosine monophosphate (cGMP)-independent manner. Furthermore, TRPA1 receptors mediate the pruritus induced by activation of PAR-2, but H2S does not interfere with this pathway. These results provide additional support for the development of new therapeutical alternatives, mainly intended for treatment of pruritus in patients unresponsive to anti-histamines.






Pruritus (or itch) is an unpleasant cutaneous sensation leading to the desire to scratch (Rothman, 1941). It acts as a physiological defense mechanism against the action of external harmful agents (Ständer et al., 2003) and can greatly interfere with the quality of life of the individual when exacerbated. Pruritus is the most common symptom of some cutaneous diseases such as urticaria, dry skin, atopic dermatitis and psoriasis, as well as some systemic disorders such as chronic renal failure, cholestasis and parasitosis (Ständer et al., 2007), and the usual treatment involves anti-histamines, either alone or supplemented with other topical and/or systemic therapies (such as corticosteroids, local anesthetics, immunomodulators and μ-opioid receptor antagonists; Patel & Yosipovitch, 2010) . However, anti-histamine-resistant pruritus is highly prevalent in some clinical settings, such as atopic dermatitis (~80%), cholestatis (80-100%) and chronic renal failure (25-50%; Greaves, 2010). In this way, the study of mediators other than histamine in the context of pruritus etiology is mandatory for the search of new therapeutic targets and tools.
Previous studies have shown that the activation of type-2 proteinase-activated receptors (PAR-2) can cause itching; in fact, the involvement of this receptor has been characterized in the pathophysiology of itching in patients with atopic dermatitis (Steinhoff et al., 2003). PARs are a group of G protein-coupled receptors, which are activated after the proteolytic cleavage of their N-terminal domain, when a new N-terminal sequence is exposed and acts as a tethered ligand that binds and activates the receptor itself (Ossovskaya, Bunnett, 2004; Steinhoff et al., 2005). PAR-2 is highly expressed in the skin (Guenther, Melzig, 2015), and is activated by a wide range of serine proteases. In addition, synthetic agonists, such as the peptides SLIGRL-NH2 and SLIGKV-NH2 activate PAR-2 receptors in rodents and humans, respectively (al-Ani et al., 1995; Bohm et al., 1996). Previous results from our laboratory show that the scratching behavior induced by either histamine or degranulation of cutaneous mast cells by compound 48/80 in mice can be effectively reduced by hydrogen sulfide H2S donors (Rodrigues et al., 2013). H2S is a colorless gas with a strong odor of rotten eggs traditionally considered as a toxic gas, although it is also generated endogenously during cysteine metabolism in mammals (Abe, Kimura, 1996). H2S plays important roles in various physiological and pathological processes and H2S donors have shown anti-inflammatory and antinociceptive effects in several experimental disease models, such as gastrointestinal (Distrutti et al., 2006; Zanardo et al., 2006), cardiac (Sivarajah et al., 2009), articular (Ekundi-Valentim et al., 2010; 2013) and periodontal disorders (Herrera et al., 2015), among others.











The PAR-2 agonist Ser-Leu-Ile-Gly-Arg-Leu-NH2 (SLIGRL-NH2) was obtained from GenScript USA Inc. (Piscataway, NJ, USA). GYY4137 was synthesized in-house as previously described elsewhere (Li et al., 2008; Le Trionairre et al., 2014). Histamine, pyrilamine, sodium hydrosulfide (NaHS), glibenclamide, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and sodium nitroprusside (SNP) were obtained from Sigma Chemical Co (St. Louis, MO, USA). TRPA1 agonist allyl isothiocyanate (AITC) and antagonist HC-030031 were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Sildenafil was suppied by Pfizer Inc. (Guarulhos, SP, Brazil).
All the drugs were dissolved in Tyrode´s solution, except HC-030031 and ODQ which were dissolved in Tyrode´s solution containing 20 and 12.8% DMSO, respectively.

Induction of scratching behavior
PAR-2-induced scratching behavior was performed and assessed according to the method described by Costa et al. (2006). One day before the experiments, the dorsal region of the animal neck was shaved and on the next day, each animal was acclimatized in a quiet room with acoustic isolation for 30 min, placed in a 12 x 20 x 17 cm (length x width x height) acrylic cage where the scratching behavior was evaluated. After this period, SLIGRL-NH2 (8-80 nmol contained in a 50 μl volume) was intradermally (i.d.) injected into the mouse back; control animals received the same volume of Tyrode´s solution. Immediately after the injection, the animals were returned to the acrylic cage, and the scratching behavior was videotaped for 30 min in a room with acoustic isolation and adapted for use of a video camera. Playback of the video served for determination of scratching behavior by trained people unaware of the treatments. Scratching behavior was quantified by counting the number of scratching bouts during the observation period. A scratching bout is considered when the mouse stretches the hind-paw toward the injected site, rapidly move the paw several times and then lowers it back to the floor. Results were expressed as the number of scratching bouts that occured during 20 min or at every 5 min intervals, as specified. From the SLIGRL-NH2 dose-response curve, we selected the 40 nmol dose for the subsequent experiments, as this dose causes a sub-maximal scratching response.

Analysis of the involvement of histamine H1-receptor in the SLIGRL-NH2-induced scratching behavior
To investigate whether histamine was involved in the SLIGRL-NH2-induced scratching behavior, we performed a dose-response curve to histamine (50-1000 nmol, i.d.) and found that 300 nmol histamine induced a scratching behavior similar to that induced by 40 nmol SLIGRL-NH2. Next, additional sets of animals were pre-treated with the histamine H1-receptor antagonist pyrilamine (30 mg/kg; i.p.) 30 min before the i.d. injection of either 40 nmol SLIGRL- NH2 or 300 nmol histamine. Control animals received the vehicle Tyrode (10 ml/kg; i.p.). Pyrilamine dose was defined based on experiments previously performed in our laboratory (not shown).

Effect of H2S donors on the SLIGRL-NH2-induced scratching behavior
Groups of animals were treated with either GYY4137 (0.01-30 nmol; i.d.) or NaHS (0.01-30 nmol; i.d.), a slow-release and a spontaneous H2S donor, respectively, which were co-injected with SLIGRL-NH2 (40 nmol).
Additional sets of animals also received different drugs which were co-injected (i.d.) with SLIGRL-NH2 (40 nmol) and NaHS (1 nmol), such as the KATP channel-blocker glibenclamide (200 nmol), the well established NO donor sodium nitroprusside (SNP; 10 nmol) or the specific soluble guanylyl cyclase inhibitor ODQ (30 μg). Control animals received the respective vehicles (50 μl).

Measurement of skin cyclic guanosine monophosphate (cGMP) contents
A separate set of 5 animals was prepared as described above. Under anestesia with inhaled isofluorane (3% in O2, v/v), each animal received six i.d. injections of the test substances (contained in 50 l) into the dorsal skin, using a randomized scheme, as previously described by Yshii et al. (2009): Tyrode´s solution, NaHS (1 nmol), the specific type V-phosphodiesterase inhibitor sildenafil (3 nmol), SNP (10 nmol) and SNP plus ODQ (30 g, injected 5 min before) concomitantly with SLIGRL-NH2 (40 nmol); in the control site, the animals were injected with 50 l of Tyrode´s solution.
Fifteen minutes post-injections, the mice were euthanized, the dorsal skin was removed and the injected sites were punched out and snap-frozen in liquid nitrogen. After grinding, the samples were weighed and homogenized with 5% trichloroacetic acid at 4°C, centrifuged (1,500 g during 10 min at 4 °C) and the supernatants were assayed for cGMP content using a commercial EIA kit (Cayman Chemical Co, MI, USA) following the manufacturer instructions.

Participation of the transient receptor potential ankyrin-1 (TRPA1) on the PAR-2-induced scratching behavior
To examine the involvement of TRPA1 on PAR-2 activation- induced scratching behavior, mice were treated with the TRPA1 antagonist, HC-030031 (20 μg; i.d.), which was injected 5 min before SLIGRL-NH2 (40 nmol) in the same site. Control animals received the corresponding vehicle (50 μl of 20% DMSO in Tyrode solution).
We also studied the effects of increasing doses of the TRPA1 agonist allyl isothiocyanate (AITC; 1-1000 nmol, i.d.) on the scratching behavior, and the effectiveness of the TRPA1 antagonist HC-030031 was analysed in another group of animals against the 1000 nmol AITC dose. Control animals received 50 μl of the HC-030031 compound vehicle.
To evaluate the effects of H2S on the pruritogenic response induced by TRPA1 activation, another set of mice received concomitant i.d. injections of NaHS (0.03-3 nmol) and AITC (1000 nmol; i.d.); control animals received 50 μl of Tyrode´s solution.

Western blot analysis
Dorsal neck skin samples from naïve mice were homogenised in TRIS buffer (50 mM, pH 7.4) containing 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1% protease inhibitor mixture (Sigma, St. Louis, MO, USA) at 4 °C using a micro grinder. After centrifugation at 1,000 g (5 min at 4°C) the resulting supernatants were separated and assayed for PAR-2 and TRPA1 expression by Western blotting. Protein concentration was determined according to Bradford (1976) and PAR-2 or TRPA1 expressions were respectively analysed using 5 μg or 20 μg of total proteins which were separated by SDS- polyacrylamide (PAGE) electrophoresis containing 12.5% or 7% PAGE (Laemmli, 1970). A monoclonal mouse anti-PAR-2 antibody (1:1500; SAM11, sc-13504 from Santa Cruz Biotechnology, Inc., TX, USA) or a rabbit polyclonal anti-TRPA1 antibody (1:1500; NB100-98841 from Novus Biologicals, LLC, CO, USA) were used. The corresponding HRP-conjugated secondary antibodies (goat anti-mouse, cat. 1721011 or goat anti-rabbit, cat 1705046; Bio-Rad Laboratories, Inc., CA, USA) were used and the immunoreactive bands were detected by chemiluminescence in a ChemiDocTM MP images system (Bio-Rad Laboratories, Inc, CA, USA) using a developing ECL substrate solution. The molecular weights of the immunoreactive bands were determined using the ImageLabTM software by comparison of their electrophoretic mobilities with those of known molecular weight standards.

Statistical analysis




Scratching behavior induced by SLIGRL-NH2
The i.d. injection of SLIGRL-NH2 (8-80 nmol) into the back of mice resulted in a scratching behavior which started immediately after the injection, peaked within the first 10 minutes and returned to baseline at 30 min (Figure 1a). As shown in Figure 1b, the total number of scratching bouts that occurred within the first 20 min after SLIGRL-NH2 injection were related to the SLIGRL-NH2 dose. As mentioned above, the sub-maximal SLIGRL-NH2 dose of 40 nmol was chosen for the subsequent experiments.






SLIGRL-NH2-induced scratching behavior is not sensitive to histamine H1-receptor antagonism
The i.d. injection of histamine (at 50, 100, 300 and 1000 nmol) in the back of mice induced a dose-dependent scratching behavior (Figure 2a). The response to 300 nmol of histamine was similar to that induced by 40 nmol of SLIGRL-NH2; however, and as shown in Figure 2b, when the histamine H1-receptor antagonist pyrilamine was administered 30 minutes before the pruritogenic stimuli (30 mg/kg; i.p.), it significantly inhibited the scratching behavior induced by histamine, but failed to affect that induced by SLIGRL-NH2. Pyrilamine alone did not show significant effects on the scratching behavior in comparison with the vehicle.






H2S donors reduce SLIGRL-NH2-induced scratching behavior
The i.d. co-injection of SLIGRL-NH2 (40 nmol) with either the slow-release H2S donor GYY4137 or the spontaneous donor NaHS at doses ranging from 0.01 to 30 nmol resulted in U-shape profiles (Figures 3a and 3b, respectively), and both GYY4137 (at 1 and 3 nmol) and NaHS (at 0.3 and 1 nmol) showed significant anti-itching effects.






The antipruritic effect of NaHS is mediated by KATP channel opening and involves NO in a cGMP-independent manner
The KATP channel blocker glibenclamide (200 nmol; i.d.) or the NO donor SNP (10 nmol; i.d.) significantly reversed the antipruritogenic effects of 1 nmol NaHS against 40 nmol SLIGRL-NH2 when co-injected into the dorsal region of the mice (Figures 4a and 4b, respectively). However, co-injection of the specific soluble guanylyl cyclase inhibitor ODQ (30 μg; i.d.) produced no significant effects (Figure 4c). The scratching responses to the administration of either glibenclamide, SNP or ODQ alone were not different than those observed with Tyrode (vehicle), and SLIGRL-NH2-induced pruritus was not significantly affected by any of these compounds.






TRPA1 involvement in the scratching behavior induced by PAR-2 activation
The antagonism of TRPA1 receptor by HC-030031 (20 μg; i.d.) significantly reduced SLIGRL-NH2-induced scratching behavior. The injection of HC-030031 alone did not cause significant changes in the behavior of scratching compared to the vehicle group (Figure 5a).
The intradermal injection of the TRPA1 agonist AITC (1, 10, 100, 300 and 1000 nmol) on the back of mice produced a significant pruritic effect at the 1000 nmol dose (Figure 5b). and this effect was significantly inhibit by the TRPA1 antagonist, HC-030031 (20 μg; i.d.; Figure 5c).
In order to test the involvement of TRPA1 in the itch-reducing effects of H2S, mice were treated with AITC and NaHS. The results shown in  Figure 5 (panel d) evidence that NaHS (0.03-3 nmol; i.d.) co-injected with AITC (1000 nmol; i.d.) did not affect the itch response evoked by the TRPA1 agonist.







As shown in Figure 6, the i.d. injection of 40 nmol SLIGRL-NH2 did not affect cGMP contents when injected either alone or co-injected with NaSH (1 nmol) or sildenafil (3 nmol) in comparison with Tyrode´s solution. However, the co-injection of SLIGRL-NH2 with SNP (10 nmol) resulted in significantly increased cGMP contents in comparison with SLIGRL-NH2 alone (55.61.3 vs. 27.13.9 pmol cGMP/g of tissue; P<0.001), and this increase was abolished when ODQ (30 g) was pre-injected into the site (23.01.6 pmol cGMP/g of tissue; P<0.001).








As shown in the Supplemental Figure, using the anti-PAR-2 antibody, immunoreactive bands of approximate molecular weights 43 and 55 kDa were detected in mouse dorsal skin homogenates, consistent with the information contained in the antibody specifications. Similarly, the anti-TRPA1 antibody revealed a protein band of approximately 127 kDa in agreement with TRPA1 molecular weight.








Several studies have demonstrated that PAR-2 activation results in histamine-independent pruritus both in humans and experimental animals (Steinhoff et al., 2003; Shimada et al., 2006; Ui et al., 2006; Reddy et al., 2008; Tsujii et al., 2008). Accordingly, in this study we show that the intradermal injection of the PAR-2 agonist SLIGRL-NH2 in the dorsal region of the mouse neck induces a dose-dependent scratching behavior which is not inhibited by pre-treatment of the animals with 30 mg/kg pyrilamine, a dose of the selective histamine H1-receptor antagonist that effectively blocks histamine effects. However, PAR-2-induced itching can be significantly reduced by the concomitant administration of H2S donors of different kinetic profiles (i.e., either spontaneous such as NaHS or slow-releasing such as the GYY4137 compound) at doses within the low nanomol range. As shown in Figure 3, NaHS was more potent than GYY4137, which should reflect the fact that, even at equimolar doses, the amount of H2S released by GYY4137 during the 20 min observation period is much lower than that immediately released by NaHS. In fact, while the total amount of the species H2S/HS-/S2- equals the given NaHS dose (although the relative abundance of each species is determined by pH; DeLeon et al., 2012), in the case of the organic compound GYY4137, Lee et al. (2011) show that H2S is released by hydrolysis at a very slow rate and in a sustained manner at physiological pH.
H2S may exert many of its biological effects via activation of KATP channels which involves S-persulfidation (S-sulfhydration; i.e., the covalent modification of thiol -SH groups present at the cysteine residues Cys6 and Cys26 located at the extracellular loop of the SUR1 subunit into hydropersulfide -SSH groups (Mustafa et al., 2009; Jiang et al., 2010). In this study, we show that the KATP channel blocker glibenclamide abolished the antipruritogenic effects of NaHS, thus confirming the participation of these channels. In this way, it is possible that depolarization of the sensory fibers that leads to itching is antagonized by the H2S-induced hyperpolarization secondary to KATP channel opening.
In addition, recent publications indicate that H2S can also regulate NO-mediated effects via different types of interactions between these two mediators, either synergistic or antagonistic. For example, the study from Yong et al. (2010) showed that although NaHS did not influence myocyte contractility, it reversed the negative inotropic effects induced by NO when administered simultaneously, and this inhibition was attributed to a direct (chemical) interaction between H2S and NO which leads to the formation of NO-/HNO (nitroxyl species; Filipovic et al., 2013), or a nitrosothiol-like species (Whiteman et al., 2006). On the other hand, in some systems (such as aorta, bladder and corpus cavernosum) the effects of H2S have been related to increased intracellular cGMP concentrations in view of its capacity to inhibit phosphodiesterases and thus potentiate the NO-mediated activation of sGC (Bucci et al., 2010; di Villa Bianca et al., 2015).
In our model, the concomitant administration of SNP with NaSH led to the reversal of the antipruritic effects of the latter. Furthermore, under sGC inhibition by ODQ administration, neither SLIGRL-NH2 nor H2S effects were altered, thus showing that cGMP does not play any significant role in these responses. In fact, these observations were confirmed by skin cGMP measurements (Figure 6), which evidenced that neither NaHS nor the specific type-V phosphodiesterase inhibitor sildenafil caused significant cGMP increases, and that, at the injected dose, ODQ was effective in preventing SNP-induced cGMP production via sGC-inhibition. In this way, NO-mediated inhibition of H2S effects may involve either the chemical interaction between these two species or the competition for any common target (for example, S-nitrosylation/nitrosation vs. S-sulfhydration of cysteine –SH groups).
In this work we also confirm the involvement of TRPA1 in the SLIGRL-NH2-induced itching, as this response was significantly reduced by the selective TRPA1 antagonist HC-030031. Indeed, the expression of both PAR-2 and TRPA1 receptors in skin samples were confirmed by Western blot, in agreement with previous studies that demonstrate that PAR-2 and TRPA1 receptors are widely expressed in both keratinocytes and primary afferent neurons innervating the skin (Santulli et al., 1995; Steinhoff et al., 2000; Dai et al., 2007). Wilson et al. (2013) have demonstrated that SLIGRL-NH2-mediated PAR-2 activation in keratinocytes promoted the release of the cytokine thymic stromal lymphopoietin (TSLP), which directly acted on a subset of TRPA1-positive sensory neurons to trigger scratching behavior. Moreover, a previous report from Wilson et al. (2011) showed that TRPA1 is linked to the activation of Mas-related G protein-coupled receptors (Mrgpr), such as the MrgprA3 and MrgprC11 members, involved in signaling histamine-independent itch, being MrgprC11 also likely to be directly activated by SLIGRL-NH2 (Lui et al., 2011).
In the present study we also show that the scratching behavior secondary to the direct TRPA1 activation by AITC was not affected by NaHS, which strongly suggests that, following PAR-2 activation, TRPA1 may represent a parallel pathway unsensitive to the anti-pruritogenic effects of H2S. Furthermore, recent studies showed that H2S added as bolus of NaHS and at high concentrations (1-10 mM) exerted proinflammatory and pronociceptive actions, by activating TRPA1 receptors present in sensory nerve fibers of the bladder ganglion cells (Streng et al., 2008) and dorsal root ganglion (Miyamoto et al., 2011; Ogawa et al., 2012).
H2S have also been reported as pruritogenic by Wang et al. (2015), as showing that the intradermal injection of the H2S donors NaHS and Na2S into the mouse back induced, in a dose-dependent manner, an intense scratching behavior via activation of T-type calcium channels. However, it is worth highlighting that the H2S donor doses used in this study were approximately 200-300 times higher than the ones used in the present study and inhibitory effects on T-type calcium channels are observed with very low concentrations (e.g. 300 nM) of slow releasing H2S donors (Tomasova et al., 2015) and sulfide (Elies et al., 2015). Taking into account the results obtained by Wang et al. (2015) and the U-shaped dose-response profiles of the H2S donors used at much lower doses in our current study (Figure 3), it becomes clear the wide array of check-points that can be targeted by H2S (at different concentrations/doses), which determine, in turn, its predominant effects in terms of pro/anti-itching activity.

Conclusions
Based on the results shown in this study, we conclude that pruritus secondary to PAR-2 activation by SLIGRL-NH2 in mice can be significantly reduced by the local administration of low nanomol doses of either spontaneous or slow-releasing H2S donors, which act via KATP channels opening and NO (in a cGMP-independent manner). Considering the high prevalence of histamine-independent pruritus in many and varied systemic diseases, such as chronic renal failure and cholestasis, our results give support to future clinical trials aiming the use of H2S-releasing compounds for the effective treatment of patients suffering form these conditions.
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